Ancriviroc

Ancriviroc (SCH-351125) is an orally active CCR5 antagonist. Ancriviroc has a broad-spectrum antiviral activity against HIV-1 isolates using CCR5 as their entry coreceptor (such as ASM 80, 92US715 and YU-2) with IC50s of 0.4-9 nM. Ancriviroc strongly inhibits the replication of R5-using HIV-1 isolates in SCID-hu Thy/Liv mice model of HIV-1 infection. Ancriviroc can be used for HIV infection research[1].

Product Specifications

CAS Number

[370893-06-4]

Product Name Alternative

SCH-351125

UNSPSC

12352005

Hazard Statement

H228-H315-H319

Target

CCR; HIV

Related Pathways

Anti-infection; GPCR/G Protein; Immunology/Inflammation

Field of Research

Infection

Smiles

CCO/N=C(C1=CC=C(C=C1)Br)/C2CCN(C3(CCN(CC3)C(C4=C([N+]([O-])=CC=C4C)C)=O)C)CC2

Molecular Formula

C28H37BrN4O3

Molecular Weight

557.52

Precautions

P210-P240-P241-P264-P280-P302+P352-P305+P351+P338-P362+P364-P370+P378

References & Citations

[1]Strizki JM, et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci U S A. 2001 Oct 23;98 (22) :12718-23.